Cargando…

Advances and Clinical Outcomes in Hodgkin Lymphoma in the Era of Novel Therapies

Detalles Bibliográficos
Autores principales:	Paviglianiti, Annalisa, Rampi, Nicolò
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003903/ https://www.ncbi.nlm.nih.gov/pubmed/36902715 http://dx.doi.org/10.3390/jcm12051928

Ejemplares similares

Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies
por: Mohty, Razan, et al.
Publicado: (2021)

Advanced Hodgkin Lymphoma: a New Era of Therapy
por: Dann, Eldad J.
Publicado: (2014)

Autologous Stem Cell Transplantation in Hodgkin Lymphoma—Latest Advances in the Era of Novel Therapies
por: Samara, Yazeed, et al.
Publicado: (2022)

Managing advanced stage Hodgkin lymphoma
por: Saikia, TK
Publicado: (2015)

The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma
por: Dogan, Ahmet
Publicado: (2022)

Vaccinations in hematological patients in the era of target therapies: Lesson learnt from SARS-CoV-2
por: Fattizzo, Bruno, et al.
Publicado: (2023)

Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era
por: Lapuz, Carminia, et al.
Publicado: (2018)

Bringing circulating tumor DNA to the clinic in Hodgkin lymphoma
por: Kurtz, David M.
Publicado: (2021)

Immunotherapies in Non-Hodgkin’s Lymphoma
por: Bezombes, Christine, et al.
Publicado: (2021)

Radiation Therapy for Advanced-Stage Hodgkin Lymphoma
por: Lockney, Natalie A., et al.
Publicado: (2020)

PET-guided treatment in advanced-stage Hodgkin lymphoma: yes but which one?
por: Rossi, Cédric, et al.
Publicado: (2019)

Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy
por: Grover, Natalie S., et al.
Publicado: (2015)

Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art
por: Martino, Massimo, et al.
Publicado: (2020)

HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART
por: Jacobson, Caron A., et al.
Publicado: (2012)

AIDS-Related Non-Hodgkin's Lymphoma in the Era of Highly Active Antiretroviral Therapy
por: Vishnu, Prakash, et al.
Publicado: (2012)

A Review of Hodgkin Lymphoma in the Era of Checkpoint Inhibitors
por: Schimmoeller, Christopher J, et al.
Publicado: (2023)

Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
por: De Re, Valli, et al.
Publicado: (2019)

Current advances in Hodgkin’s lymphoma
por: Vadakara, Joseph, et al.
Publicado: (2019)

Second cancer risk following Hodgkin lymphoma
por: Sud, Amit, et al.
Publicado: (2017)

Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents
por: Faisal, Muhammad Salman, et al.
Publicado: (2023)

Clinical Management of Long-Term Survivors after Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma
por: Bari, Alessia, et al.
Publicado: (2022)

Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas
por: Leslie, Lori A.
Publicado: (2021)

Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances
por: Derenzini, Enrico, et al.
Publicado: (2011)

PET-adapted approaches to primary therapy for advanced Hodgkin lymphoma
por: Lang, Noemie, et al.
Publicado: (2020)

Evaluating Disparities in Proton Radiation Therapy Use in AHOD1331, a Contemporary Children's Oncology Group Trial for Advanced-Stage Hodgkin Lymphoma
por: Mailhot Vega, Raymond B., et al.
Publicado: (2021)

A Review on the Impact of Body Mass Index on Outcomes in Pediatric Leukemia
por: Paviglianiti, Annalisa
Publicado: (2020)

Yescarta: A New Era for Non-Hodgkin Lymphoma Patients
por: AlDallal, Salma M
Publicado: (2020)

Ikaros as a downstream mediator of BCR blockade therapy in B-cell non-Hodgkin lymphoma
por: Ribeiro, Marcelo Lima, et al.
Publicado: (2022)

Editorial: Advances in the treatment of Hodgkin lymphoma
por: Mei, Matthew, et al.
Publicado: (2023)

Advances in the treatment of Hodgkin's lymphoma (Review)
por: Che, Yuxuan, et al.
Publicado: (2023)

Hypotension Associated with Advanced Hodgkin Lymphoma
por: Mangla, Ankit, et al.
Publicado: (2014)

Recent advances in the management of Hodgkin lymphoma
por: Villasboas, Jose C., et al.
Publicado: (2016)

HIV-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence, outcome, and evolution of CD4+ T cell lymphocytes
por: Egger, Matthias
Publicado: (2010)

Expanding the bacterial origins of nodular lymphocyte-predominant Hodgkin lymphoma
por: Gandhi, Maher K., et al.
Publicado: (2023)

Progress in understanding the biology of nodular lymphocyte-predominant Hodgkin lymphoma
por: Straus, David J.
Publicado: (2021)

Improving Outcomes After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma in the Brentuximab Vedotin Era
por: Hegerova, Livia, et al.
Publicado: (2017)

CHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi
por: Gopal, Satish, et al.
Publicado: (2016)

Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
por: Randall, Michael P., et al.
Publicado: (2023)

Minimising the Toxicities of First Line Hodgkin Lymphoma Treatment in the Modern Era
por: Follows, Annabel M., et al.
Publicado: (2022)

FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
por: Barrington, Sally F., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1krvsp15p7p1sm3fn3k1imaf0i